The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The evolving role of autoSCT in NDMM: an overview of clinical trial evidence
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the ongoing debate surrounding the role of autologous stem cell transplantation (autoSCT) in newly diagnosed multiple myeloma (NDMM). Dr Beksac highlights several clinical trials investigating the optimal induction regimens. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
